Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug

benzinga.com/news/health-care/25/06/45723383/bristol-myers-inks-11-billion-licensing-pact-with-biontech-for-bispecific-cancer-drug

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization agreement.
The pact focuses on BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types.
Under the agreement, BioNTech and Bristol…

This story appeared on benzinga.com, 2025-06-02 14:14:16.
The Entire Business World on a Single Page. Free to Use →